Norroy Bioscience develops precision nuclear medicines targeting difficult-to-treat cancers, including pancreatic, kidney, and prostate cancers, utilizing proprietary radiopharmaceutical technology. The company addresses unmet clinical needs in oncology by providing targeted therapies that enhance treatment efficacy and patient outcomes.
Funding
Funding not disclosed
Founders
Product
Problem
Many cancers, such as pancreatic, kidney, and prostate cancers, are difficult to treat effectively with existing therapies. There is an unmet need for more targeted and efficacious treatments that can improve patient outcomes in these challenging oncology indications.
Solution
Norroy Bioscience develops precision nuclear medicines that target difficult-to-treat cancers using proprietary radiopharmaceutical technology. The company focuses on creating targeted therapies designed to enhance treatment efficacy and improve patient outcomes. Their approach involves developing both first-in-class and best-in-class radiopharmaceuticals, with a focus on addressing unmet clinical needs in areas like urological and gastrointestinal tumors. Norroy Bioscience leverages its clinical translation technology platform to rapidly screen and develop promising drug candidates.
Target Audience
The primary target audience includes oncology physicians and patients with difficult-to-treat cancers, as well as hospitals and clinics specializing in nuclear medicine and cancer treatment.
Features
- Focus on developing innovative radiopharmaceuticals for oncology
- Pipeline includes both first-in-class and best-in-class drug candidates
- Targeting urological and gastrointestinal tumors
- Clinical translation technology platform for rapid drug screening
- In-house GMP-standard manufacturing facility for radiopharmaceutical production
- Developing theranostic radiopharmaceuticals for diagnosis and therapy